(Información remitida por la empresa firmante)
7. https://www.ncbi.nlm.nih.gov/books/NBK448111/ Consultado en junio de 20258. Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Disponible en: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov.
9. Meyskens FL Jr, Gerner EW. Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent. Clin Cancer Res. 1999 May;5(5):945-51
10. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57.
11. Desai A, et al. Outcomes Following GD2-Directed Post consolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children’s Oncology Group. J Clin Oncol. 2022 Jul; JCO2102478.
12. Basta NO, Halliday GC, Makin G, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115(9):1048-1057. doi:10.1038/bjc.2016.302.
13. London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123:4914-23.
14. FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA, Consultado 04.07.25
Logo — https://mma.prnewswire.com/media/597589/4648918/Norgine_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/swissmedic-aprueba-ifinwil-eflornitina-para-ninos-diagnosticados-con-neuroblastoma-de-alto-riesgo-hrnb-302499276.html
